About this webinar
The number of people with diabetes, currently ca. 415 million worldwide, is anticipated to increase up to 550 million or even more by 2030. Despite significant advantages in the management strategies that lessen atherosclerotic CVD risk factors, CVD has remained the leading cause of morbidity and mortality in patients with Type-2 diabetes. The good news is that fatal CVD outcomes have declined significantly in both Type-1 and Type-2 diabetes between 1998 and 2014.
The 2019 Joint ESC/EAS Dyslipidaemia Guidelines again reiterated that diabetes mellitus itself is an independent risk factor for CVD and is associated with a higher risk of CVD, even more so in women, requiring lipid modification therapy.
This webinar comprises a 15-min presentation, in which Prof Ray will cover what the new Guidelines recommend about management of patients with diabetes, looking at risk assessment and treating to LDL-C goal for their level of risk, followed by Q&A.
Take the opportunity to understand how the new Guidelines apply to your practice, and put your questions on this topic to Prof Ray in this interactive webinar.
This webinar is primarily suited to physicians in internal medicine, cardiology, diabetology, and endocrinology.
It is highly relevant to physicians in general practice, nurses and healthcare practitioners working in lipid clinics, in cardiovascular prevention, in diabetes and in many other clinics training care of patients with cardiovascular or metabolic diseases.
Others who will find the educational content of this webinar to be relevant include scientists working in cardiovascular epidemiology and in basic cardiovascular research, and persons employed in the pharma industry.
ABOUT THE PRESENTER
Kausik Ray is Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Disease Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London and a Consultant Cardiologist.
Professor Ray’s research interests focus on preventing the global consequences of atherosclerosis through large-scale population studies evaluating the burden of disease and improving risk prediction and through the study of novel therapies in the setting of multi-centre international clinical trials to offer solutions to help prevent death and disability from cardiovascular disease. As such, he is the global PI of several ongoing Cardiovascular trials and registries.
The impact of his novel research findings has contributed to current US and European Guidelines amongst others.
Since 2017 he has served on the European Atherosclerosis Society’s Executive Committee and he has this year been elected the Society’s President Elect.
In 2014 he independently initiated and obtained funding for the EAS FH Studies Collaboration, the first global registry of its kind, now encompassing over 68 countries and approximately 60,000 cases, for which he is the lead.
EAS has independently organised all matters related to these webinars, including content and presenters. We acknowledge financial support, in the form of an unrestricted educational grant, received from Sanofi and Regeneron in support of the programme.
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. For more than 50 years the Society’s exp...
Share this webinar